Asfotase alfa

Asfotase alfa
Clinical data
Trade names Strensiq
Routes of
administration		 Subcutaneous injection
Legal status
Legal status

Asfotase alfa is a drug used in the Treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia[1][2]

Asfotase alfa is manufactured by Alexion Pharmaceuticals and It was granted breakthrough therapy designation by FDA in 2015.

References

  1. ↑ CDER Breakthrough Therapy Designation Approvals
  2. ↑ FDA approves new treatment for rare metabolic disorder

External links

This article is issued from Wikipedia - version of the Saturday, April 30, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.